Melanotan II plus light therapy for vitiligo repigmentation
Part of Skin clinical trials.
This trial tests whether adding a daily nasal spray (Melanotan II) to light therapy helps restore color in stable vitiligo patches. It may be a good option for adults with mild to moderate nonsegmental vitiligo that hasn't changed in at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have nonsegmental vitiligo that has been stable (no new spots or spreading) for at least 6 months
- Your vitiligo patches cover between 3% and 20% of your body
- You are willing to have phototherapy (light treatment) sessions and avoid other vitiligo treatments during the study
- If you can become pregnant, you agree to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This study tests whether a new tablet called LW402 can help restore skin color in people with non-segmental vitiligo (white patches that spread unpredictably across the body). The medication works by targeting immune cells that attack skin pigment.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests a new injection called GR2301 combined with light therapy to treat vitiligo, a condition that causes loss of skin color. The study aims to see if this combination helps restore skin color and reduce white patches.
Hear when a new NonSegmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.